What is GlucoTrack, Inc. (GCTK) stock price today?

GlucoTrack, Inc. (GCTK) is currently trading at $1.03, down 7.21% today.

What is GCTK P/E ratio?

GlucoTrack, Inc.'s P/E ratio is -0.01. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GCTK return on equity (ROE)?

GlucoTrack, Inc.'s return on equity (ROE) is -581.98%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is GlucoTrack, Inc.'s market cap?

GlucoTrack, Inc. has a market capitalization of $822087.

NASDAQ · Medical - Instruments & Supplies

GlucoTrack, Inc. (GCTK) Stock

$1.03 -7.21% NASDAQ: GCTK Healthcare

Valuation

Metric	Value
Price	$1.03
Market Cap	$822087
P/E Ratio	-0.01
P/B Ratio	-0.15
P/S Ratio	0.00
EPS (TTM)	$-21.56
52-Week High	$136.29
52-Week Low	$1.03
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-581.98%
ROA	-387.72%
ROCE	454.19%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.01
Current Ratio	1.60

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-4.0M	$-4.0M	$-7.0M	$-15.0M	$-16.0M
Net Profit	$-4.0M	$-4.0M	$-7.0M	$-23.0M	$-19.0M
EPS	$-394.80	$-429.90	$-574.50	$-911.40	$-323.40
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$6.0M	$2.0M	$5.0M	$6.0M	$8.0M
Total Liabilities	$1.0M	$1.0M	$2.0M	$19.0M	$5.0M
Cash	$6.0M	$2.0M	$4.0M	$6.0M	$7.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing GlobeNewswire · Jul 17, 2026 Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives GlobeNewswire · Jul 17, 2026 UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform GlobeNewswire · Jul 16, 2026 Glucotrack Completes Lōkahi Therapeutics Business Combination, Creating AI-Driven Healthcare Platform InvestorsHub · Jul 15, 2026 BC-Most Active Stocks Associated Press · Jul 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-4.0M	$-4.0M	$-7.0M	$-12.0M	$-15.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-4.0M	$-4.0M	$2.0M	$1.0M	$2.0M
Free Cash Flow	$-4.0M	$-4.0M	$-7.0M	$-13.0M	$-15.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.01
FCF Yield	-1776.73%
Quick Ratio	0.46
Interest Coverage	-54.25
Return 1Y	-90.29%
Return 3Y	-99.98%
Return 5Y	-100.00%

Ownership

Insiders Held0.76%

Institutions Held3.72%

Institutions Float Held3.75%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AKANAkanda Corp.	$1.76	-1.12%	-0.01	$56964	0.00%
BBLGBone Biologics Corp	$0.47	-0.43%	-0.26	$845628	0.00%
BGMSBio Green Med Solution, Inc.	$0.85	+3.41%	-0.24	$4.69M	0.00%
DHAIDIH Holding US, Inc.	$0.02	+0.00%	0.00	$41853	0.00%
HSCSHeartSciences Inc.	$3.18	+4.61%	-1.36	$6.87M	0.00%

About GlucoTrack, Inc.

GlucoTrack, Inc. is led by CEO Paul V. Goode, employs 11 people, headquartered in IL, publicly traded since 2013.

GlucoTrack, Inc. (GCTK) stock trades at $1.03 with a market capitalization of $822087. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of -0.15, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.03 and $136.29, and currently trades 99.2% below its 52-week high.

On profitability, GlucoTrack, Inc. generates a return on equity (ROE) of -581.98%, return on capital employed of 454.19%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides